The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

Multispecific antibody shows promise for B cell lymphoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Nutcracker Therapeutics Inc., a biotechnology company focused on developing RNA therapies through its proprietary technology platform, presented a poster on NTX-472, its new preclinical drug candidate for B cell lymphoma, at the 2024 American Society of Clinical Oncology Annual Meeting in Chicago.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Drugs & Targets

MAIA Biotechnology, BeiGene announce clinical supply agreement

MAIA Biotechnology Inc. and BeiGene entered into a clinical supply agreement to assess the efficacy of THIO, MAIA Biotechnology’s small molecule telomere-targeting anticancer agent, in combination with BeiGene’s immune checkpoint inhibitor tislelizumab, in three cancer indications. The single-arm pivotal phase II trials will study the drug combination in hepatocellular carcinoma, small cell lung cancer, and colorectal cancer.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account